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were administrated with high dose of penehyclidine hydrochloride
(H-PHC; 1 mg/kg bodyweight)by i.v. 30min before sham surgery; c).
Ischemia reperfusion (I/R) group: The rats were subjected to a
30min LAD coronary artery ligation followed by 3h reperfusion; d).
I/RþL-PHC group: The rats were administrated with low dose of
PHC (L-PHC; 0.1 mg/kg bodyweight) 30min before I/R; e). I/RþM-
PHC group: The rats were administrated with moderate dose of PHC
(M-PHC; 0.3 mg/kg bodyweight) 30min before I/R; f). I/RþH-PHC
group: The rats were injected with H-PHC (1 mg/kg bodyweight)
30min before I/R. Cardiac function was measured by echocardiog-
raphy after 3h reperfusion. Blood samples were collected. Then, the
activities and levels of myocardial enzymes and antioxidant en-
zymes in serum were detected. Evans blue/TTC double staining was
performed to assess infarct size. Cardiomyocyte apoptosis was
evaluated by TUNEL assay. The release of inﬂammatory cytokines
and inﬂammatory mediators was detected by ELISA. Western blot
was performed to analyze the expression of COX-2, p-IkB, IkB and
NF-kB.
RESULTS We found that PHC improved cardiac function by elevating
ejection fraction (EF), fractional shortening (FS) and left ventricular
end systolic pressure (LVESP), and downregulating left ventricular
end-diastolic pressure (LVEDP). PHC treatment remarkably decreased
the activities of creatine kinase (CK), aspartate aminotransferase
(AST), lactate dehydrogenase (LDH) and malondialdehyde (MDA)
content, and increased superoxide dismutase (SOD) activity. Addi-
tionally, PHC reduced the infarct size and the apoptotic rate of car-
diomyocytes in a dose dependent manner. Administration of PHC
signiﬁcantly decreased serum IL-1b, TNF-a, PEG-2 and IL-6 levels and
myocardium COX-2 level. Meanwhile, the expression levels of p-IkB
and NF-kB were downregulated, while IkB expression was upregu-
lated. These results suggest that PHC exert dose-dependent effects
on I/R-induced myocardial injury by inhibiting oxidative stress,
apoptosis and inﬂammation, and reduce the levels of nuclear NF-kB
and p-IkB.
CONCLUSIONS PHC presented signiﬁcantly dose dependent effects
on myocardial IRI by inhibiting inﬂammation, oxidative stress and
apoptosis, and reducing the level of nuclear NF-kB and p-IkB.GW26-e1245
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OBJECTIVES Antiplatelet treatment has been proved to be an effec-
tive strategy for the prevention of cardiovascular disease (CVD).
However, a major disadvantage of this strategy is the increasing risk of
hemorrhages. Developing new platelet inhibitors with minimal
adverse effects is important for clinical treatment of CVD. Atractyle-
nolideII(ATII) and III(ATIII) are the major active components in
Atracylodes macrocephala. The effects of the components including
anti-inﬂammatory and anti-cancer have been demonstrated. Howev-
er, their effects on platelet activation are unknown. Therefore, We
explored the effects of ATII and ATIII on platelet activities such as
platelet aggregation, platelet spreading, thrombus formation and so
on. We also investigated the effects of ATII and ATIII on essential
signaling mediator in platelet activation.
METHODS Human platelets were adjusted to 310⁸platelets/ml for
platelet aggregation. ATII, ATIII and Acetylsalicylic acid were incu-
bated with the platelets for 3 min prior to stimulation, respectively.
When the platelet aggregation was terminated, the target proteins
were detected to detect the phosphorylation levels of signaling mol-
ecules by Western blotting. For platelet spreading on immobilized
ﬁbrinogen, platelets were incubated with ATII and ATIII respectively
for 3min and allowed to spread on immobilized ﬁbrinogen. The colt
reaction was done as following, human platelet-depleted plasma was
mixed with washed human platelets to a concentration of 4108/ml
and was incubated with ATIIand AT III for 3min respectively. Plasma
was induced to coagulate with 0.4U/ml thrombin. We examined
thrombosis formation by FeCl3-induced carotid artery injury murine
thrombosis model. After mice were treatment with ATII(ATIII) at
60mg/kg dose by oral administration, carotid artery blood ﬂow was
monitored.
RESULTS Compared to Acetylsalicylic acid, ATII(ATIII) inhibited
platelet aggregation with lower concentration(10mM) in response toathrombin and collagen. Akt and other signaling molecules such as
p-38, Erk have been proved to play critical roles in platelet activa-
tion. Akt Ser473phosphorylation levels were signiﬁcantly diminished
for ATII(ATIII) treatment in response toathrombin, but no changes
were found in the phosphorylation levels of p-38 and Erk. The
average size of the platelets that spread on Fg were 1900.41059.86
pixels for ATII10mM,21851687.07 pixels for ATIII10mM versus
9508.762107.95 pixels for the platelets in the presence of DMSO. In
the FeCl3-induced carotid artery thrombosis model, the average time
to ﬁrst occlusion was 12.19 min for the ATII,and 9.67 min for ATIII
mice, in contrast to 6.76min in control mice. The average ratio of
clot retraction of ATII with platelets was 0.16590.0115, ATII
with platelets was 0.28920.0118 versus DMSO with platelets
0.71830.0359.
CONCLUSIONS The work demonstrates that ATII and AT III inhibit
platelets aggregation, spreading, clot retraction and arterial throm-
bosis formation in vivo. The results suggest that ATII& III have the
potential to be an efﬁcient platelet inhibitors.
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OBJECTIVES Our previous studies found that cardiac stem cells
(CSCs) transplantation improved the ventricular ﬁbrillation
threshold (VFT) in myocardial infarction (MI) rats. However, the
mechanisms remain unclear. Therefore, we sought to explore the
mechanisms.
METHODS MI was induced in 30 male Sprague-Dawley rats. 2 weeks
later, animals were randomized to receive 5106 CSCs labeled with
PKH26 in phosphate buffer solution(PBS)(20 rats) or PBS (10 rats)
alone injection into the infarcted anterior ventricular free wall.
After that, 10 rats with CSCs transplantation received PHA665752
(Hepatocyte Growth Factor/c-Met Inhibitor, 15mg/kg) in PBS and
DMSO (PHA665752 group), 10 rats with CSCs transplantation
received PBS and DMSO (CSC group) and 10 rats with PBS injection
received PBS and DMSO (PBS group) via tail vein injection every
day for 2 weeks. Then the VFTs were measured. Labeled CSCs were
observed in 5mm cryostat sections from each heart to detect the
myocardial ﬁbrosis.
RESULTS Comparisons of CSC group, the VFTs were deteriorative in
PHA665752 group
(PHA665752 group vs. CSC group vs. PBS group:
infarct zone: 3.91.7mA vs. 10.31.9mA vs. 3.40.7mA p＜0.05
infarct marginal zone: 4.21.4mA vs. 9.71.4mA vs. 2.90.7mA
p＜0.05
non-infarct zone: 2.90.9mA vs. 9.11.1mA vs. 2.60.7mA p＜0.05).
Masson detection showed that the myocardial ﬁbrosis in PHA665752
group was obviously more severity than that in CSCs group.
CONCLUSIONS PHA665752, hepatocyte growth factor/c-Met inhibi-
tor, reduces the VFT and enhances the myocardial ﬁbrosis in MI rats
treated with CSCs transplantation, which indicates that CSCs para-
crining hepatocyte growth factor ameliorate myocardial ﬁbrosis
leading to VFT improvement.
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OBJECTIVES We had reported that the current density of apamin-
sensitive SK channels was signiﬁcantly increased in AF group with
persistent atrial ﬁbrillation than SR group. The purpose of this
study was to investigate whether the current density increase of
SK channels in patients with persistent atrial ﬁbrillation was
because of its differential expression between the sinus rhythm (SR)
and persistent atrial ﬁbrillation patients and whether SK3 channel
is involved in electrical remodeling of human persistent atrial
ﬁbrillation.
METHODS The right atrial appendage myocytes were obtained from
16 sinus rhythm (SR) and 14 persistent atrial ﬁbrillation patients
